Issues in Oral Nanoparticle Drug Carrier Uptake and Targeting

Some of the broader issues relating to the exploration of the use of nanoparticulate drug carriers by the oral route to achieve absorption of molecules which are poorly absorbed from the gastrointestinal tract are considered briefly here. These relate to both the pharmaceutical and biological characteristics of the carrier and carrier-gut interactions, the dynamic nature of such interactions, the varied modes of uptake, and the difficulties in targeting to the gut epithelium to encourage more efficient uptake of nanoparticles. These have the unhelpful habit of aggregating and flocculating hence increasing their effective size, when small size aids uptake and translocation. Post-absorption events can be equally hazardous and need further research. The question is asked whether or not it is wise load the gut lumen with molecules such as insulin even when protected in a carrier, and the suggestion is made that targets need to be rethought. The epithelium of the gut and the lymphoid tissue itself offers much scope for therapeutic interventions through nanoparticle delivery.

[1]  Baljit Singh,et al.  Effect of physiological media on the stability of surface‐adsorbed DNA‐dendron‐gold nanoparticles , 2003, The Journal of pharmacy and pharmacology.

[2]  Andreas Frey,et al.  Influence of targeting ligand flexibility on receptor binding of particulate drug delivery systems. , 2003, Bioconjugate chemistry.

[3]  L. Steidler Genetically engineered probiotics. , 2003, Best practice & research. Clinical gastroenterology.

[4]  Mitsuru Hashida,et al.  Factors affecting drug and gene delivery: effects of interaction with blood components. , 2002, Critical reviews in therapeutic drug carrier systems.

[5]  J. Seegers Lactobacilli as live vaccine delivery vectors: progress and prospects. , 2002, Trends in biotechnology.

[6]  M. Akashi,et al.  Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[7]  David J Brayden,et al.  Oral vaccination in man using antigens in particles: current status. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[9]  N Hussain,et al.  Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. , 2001, Advanced drug delivery reviews.

[10]  Ming-Qing Du,et al.  Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy , 2001, The Lancet.

[11]  I. Stamenkovic,et al.  CD44 as a receptor for colonization of the pharynx by group A Streptococcus. , 2000, The Journal of clinical investigation.

[12]  N. Hussain Ligand-mediated tissue specific drug delivery. , 2000, Advanced drug delivery reviews.

[13]  W. Fiers,et al.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. , 2000, Science.

[14]  J. Badger,et al.  Motility Is Required To Initiate Host Cell Invasion by Yersinia enterocolitica , 2000, Infection and Immunity.

[15]  C. Lehr,et al.  Lectin-mediated drug delivery: the second generation of bioadhesives. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[16]  D. Favre,et al.  Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria , 1999, Infection and Immunity.

[17]  J Collinge,et al.  Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. , 1999, Science.

[18]  J. Beaulieu,et al.  Insulin Modulates Cellular Proliferation in Developing Human Jejunum and Colon , 1999, Neonatology.

[19]  David J Brayden,et al.  Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines , 1998 .

[20]  A. Gebert,et al.  Kinetics of particle uptake in the domes of Peyer's patches. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[21]  Langer,et al.  New advances in microsphere-based single-dose vaccines. , 1997, Advanced drug delivery reviews.

[22]  Alexander T. Florence,et al.  Enhanced Oral Uptake of Tomato Lectin-Conjugated Nanoparticles in the Rat , 1997, Pharmaceutical Research.

[23]  Alexander T. Florence,et al.  The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual , 1997, Pharmaceutical Research.

[24]  T. Saito,et al.  Selective delivery of pepleomycin to esophageal lymph nodes by activated carbon particles. , 1993, Anticancer research.

[25]  V. Bocci Absorption of Cytokines via Oropharyngeal-Associated Lymphoid Tissues , 1991, Clinical pharmacokinetics.

[26]  D. Lauffenburger,et al.  Specific adhesion of glycophorin liposomes to a lectin surface in shear flow. , 1990, Biophysical journal.

[27]  A. Axon,et al.  INTESTINAL PERMEABILITY IN COELIAC DISEASE , 1983, The Lancet.

[28]  Alexander T. Florence,et al.  Utilizing Bacterial Mechanisms of Epithelial Cell Entry: Invasin-induced Oral Uptake of Latex Nanoparticles , 2004, Pharmaceutical Research.

[29]  E. Lavelle,et al.  Targeted delivery of drugs to the gastrointestinal tract. , 2001 .

[30]  P. Pernet,et al.  Intestinal absorption and permeability in human immunodeficiency virus-infected patients. , 1999, Scandinavian journal of gastroenterology.

[31]  J. Behr,et al.  Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway , 1999, Gene Therapy.

[32]  M. Suckow,et al.  Oral vaccination of animals with antigens encapsulated in alginate microspheres. , 1999, Vaccine.

[33]  K. Yip,et al.  Interspecies Uptake of Polymeric Microspheres , 1998 .

[34]  A T Florence,et al.  Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles. , 1994, Journal of drug targeting.

[35]  J. Eldridge,et al.  Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. , 1989, Advances in experimental medicine and biology.

[36]  I. Leodolter [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.